Information  X 
Enter a valid email address

Induction Healthcare (INHC)

  Print      Mail a friend

Tuesday 19 January, 2021

Induction Healthcare

Directorate Change

RNS Number : 1494M
Induction Healthcare Group PLC
19 January 2021

19 January 2021


Induction Healthcare Group PLC


("Induction", the "Company", or the "Group")


Directorate change


Induction, a leading healthcare technology company that helps achieve digital transformation for hospitals, announces that Shelley Fraser has resigned from her position as Chief Financial Officer and from the Board with immediate effect.


She will leave the Company following a short handover period to ensure an orderly transition of responsibilities to Olly Drake, former CFO of Zesty Ltd, who will be Interim Group CFO. Olly previously worked at BDO and was UK Finance Director at Next Fifteen Communications Group PLC. The Company will commence a search for Shelley's successor during the current quarter.


The Company's current trading and outlook remain in line with previous guidance.


Chris Spencer, Induction Non-Executive Chair said:

"On behalf of the Board, I would like to thank Shelley for her contribution during her time with us and we wish her well for the future. We look forward to providing a further update on the Company's progress in 2021."






Induction Healthcare

Via FTI Consulting

Dr Hugo Stephenson, Joint Chief Executive Officer

James Balmain, Joint Chief Executive Officer

Numis Securities (Nominated Adviser and Broker)

+44 (0) 207 260 1000

James Black / Freddie Barnfield / Huw Jeremy

FTI Consulting

+44 (0) 203 727 1000

Jamie Ricketts / Elena Kalinskaya / Sam Purewal



About Induction


Induction (INHC.LSE) is a UK-based leading healthcare technology company enabling the digital transformation of secondary care. This is done by rolling up smaller solutions that are loved by doctors, hospital staff and patients and giving those solutions the infrastructure, credibility and interoperability they need to achieve commercial success at scale.


Over 190,000 hospital doctors across multiple territories, including the UK, Ireland, Australia and South Africa - as well as a rapidly growing cohort of over 140,000 patients - choose to use Induction products over traditional methods of managing care.


Induction helps healthcare professionals deliver better care more efficiently via a suite of technology platforms, including Induction Switch, Induction MicroGuide, Induction Zesty and Induction HealthStream.


Induction Zesty is a leading provider of patient portals to NHS Hospitals in the UK, enabling hospital patients to manage their care direct from their smartphone. Induction Zesty removes the friction from everyday health related tasks, like booking and managing appointments, enabling remote patient monitoring, and sharing copies of electronic medical records. 


Induction HealthStream is a proprietary data integration platform that reads and writes patient demographic, appointment and clinical record data between a growing number of hospital EHR systems and the Induction platforms.


Induction Switch is the number one healthcare collaboration app in the UK, used by the majority of hospital doctors within the NHS. The app helps to increase productivity and enhance communication by securely sharing phone numbers and bleeps, bookmarks, documents and messages in a clinical setting. 


Induction MicroGuide provides medical organisations, including most hospital trusts within the NHS, with the ability to collaboratively create, edit, and publish their own local medical guidelines in a secure and locally administrated environment.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t